Cost-effectiveness of hepatitis C screening and treatment in low-income, primarily hispanic baby boomers

Christopher S. Hollenbeak, Andrea Rochat, Asher C. Hollenbeak, Aro N. Choi, Julio Gutierrez, Barbara J. Turner

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


The cost- effectiveness of hepatitis C virus (HCV) screening and treatment was examined in low-income, primarily Hispanic baby boomers born 1945- 1965 using a Markov model of the natural history of HCV. The model was parameterized using costs and diagnostic data from 2008- 2016 and from literature on disease progression and effectiveness of screening and treatment using direct acting anti- viral (DAA) therapy. The incremental cost- effectiveness ratio (ICER) was computed from the perspective of Medicare as payer, calculated over 20 years, and discounted at 3% per year. In the base case, HCV screening cost $3,334 versus $3,797 for no screening, and yielded more quality- adjusted life years (QALYs; 14.08 vs 13.96, respectively). The ICER for screening was still less than $20,000 per additional QALY with drug costs up to $100,000. Among low-income Hispanics, HCV screening was less costly for Medicare and more effective than no screening under most assumptions. This analysis supports investment in screening and treatment in Hispanics.

Original languageEnglish (US)
Pages (from-to)1053-1067
Number of pages15
JournalJournal of Health Care for the Poor and Underserved
Issue number3
StatePublished - Aug 2019

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'Cost-effectiveness of hepatitis C screening and treatment in low-income, primarily hispanic baby boomers'. Together they form a unique fingerprint.

Cite this